N-(4-chlorobenzyl)-8-fluoro-4-hydroxy-6-(hydroxymethyl)-3-quinolinecarboxamide | 228726-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(4-chlorobenzyl)-8-fluoro-4-hydroxy-6-(hydroxymethyl)-3-quinolinecarboxamide
• 英文别名: N-[(4-chlorophenyl)methyl]-8-fluoro-6-(hydroxymethyl)-4-oxo-1H-quinoline-3-carboxamide
• CAS: 228726-66-7
• 化学式: C₁₈H₁₄ClFN₂O₃
• 分子量: 360.772
• InChiKey: QMYGMFCJUNLCIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(4-chlorobenzyl)-8-fluoro-4-hydroxy-6-(hydroxymethyl)-3-quinolinecarboxamide 在 2,4,6-三甲基吡啶 、 4-二甲氨基吡啶 、 甲基磺酰氯 、 lithium chloride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 以89%的产率得到N-(4-chlorobenzyl)-6-(chloromethyl)-8-fluoro-4-hydroxy-3-quinolinecarboxamide
  参考文献：
  名称：

  The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

  摘要：

  Discovery efforts were focused on identifying a non-nucleoside antiviral for treating infections caused by human cytomegalovirus (HCMV) with equal or better potency and diminished toxicity compared to current therapeutics. This Letter describes the HCMV DNA polymerase inhibition and in vitro antiviral activity of various 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.094
• 作为产物：
  描述：

  S-phenyl 3-((4-chlorobenzyl)carbamoyl)-8-fluoro-4-hydroxyquinoline-6-carbothioate 在 锂硼氢 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 以82%的产率得到N-(4-chlorobenzyl)-8-fluoro-4-hydroxy-6-(hydroxymethyl)-3-quinolinecarboxamide
  参考文献：
  名称：

  The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase

  摘要：

  Discovery efforts were focused on identifying a non-nucleoside antiviral for treating infections caused by human cytomegalovirus (HCMV) with equal or better potency and diminished toxicity compared to current therapeutics. This Letter describes the HCMV DNA polymerase inhibition and in vitro antiviral activity of various 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.094

文献信息

• 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
  申请人：Pharmacia & Upjohn Company

  公开号：US06093732A1

  公开（公告）日：2000-07-25

  The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula I ##STR1## These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.

  本发明提供了式I的4-羟基喹啉-3-甲酰胺和肼化合物。这些化合物可用于治疗或预防疱疹病毒感染，特别是人类巨细胞病毒感染。
• Quinolinecarboxamides as antiviral agents
  申请人：Pharmacia & Upjohn Company

  公开号：US06248739B1

  公开（公告）日：2001-06-19

  The present invention provides a compound of formula I which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

  本发明提供了一种具有化学式I的化合物，可用作抗病毒剂，特别是用于对抗疱疹病毒家族的药物。
• [EN] 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS<br/>[FR] 4-HYDROXYQUINOLINE-3-CARBOXAMIDES ET HYDRAZIDES UTILISES COMME AGENTS ANTIVIRAUX
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：WO1999032450A1

  公开（公告）日：1999-07-01

  (EN) The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula (I). These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.(FR) La présente invention concerne des composés de 4-hydroxyquinoline-3-carboxamide et d'hydrazide représentés par la formule (I). Ces composés servent dans le traitement ou la prévention d'infections à virus herpétique, en particulier, de l'infection à cytomégalovirus humain.

  本发明提供了公式（I）的4-羟基喹啉-3-羧酰胺和肼类化合物。这些化合物可用于治疗或预防疱疹病毒感染，特别是人类巨细胞病毒感染。
• [EN] QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS<br/>[FR] QUINOLINECARBOXAMIDES AGENTS ANTIVIRAUX
  申请人：UPJOHN CO

  公开号：WO2000040561A1

  公开（公告）日：2000-07-13

  The present invention provides a compound of formula (I) which is useful as antiviral agents, in particular, as agents against viruses of the herpes family.

  本发明提供了一种化合物，其化学式为(I)，可用作抗病毒剂，特别是用于对抗疱疹病毒家族的病毒。
• Method of preventing or treating atherosclerosis or restenosis
  申请人：——

  公开号：US20040186131A1

  公开（公告）日：2004-09-23

  The present invention provides a method of preventing or treating atherosclerosis or restenosis in mammals, which comprises administering an effective amount of a compound selected from the group consisting of structures of Formulas I to XV: 1 wherein the various groups in the Formulae are defined herein.

  本发明提供了一种预防或治疗哺乳动物动脉粥样硬化或再狭窄的方法，该方法包括施用有效量的选自由式I至XV的结构组成的组的化合物： 1 其中式中各基团的定义见本文。